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Abstract
Atypical antipsychotics are also used in the treatment of anxiety-related disorders. Clinical and preclinical evidence regarding
their intrinsic anxiolytic efficacy has been mixed. In this study, we examined the potential anxiolytic-like effects of risperidone
and olanzapine, and compared them with haloperidol, chlordiazepoxide (a prototype of sedative–anxiolytic drug) or citalopram (a selective serotonin reuptake inhibitor). We used a composite of two-way avoidance conditioning and acoustic startle
reflex model and examined the effects of drug treatments during the acquisition phase (Experiment 1) or extinction phase (Experiments 2 and 3) on multiple measures of conditioned and unconditioned fear/anxiety-like responses. In Experiment 4, we
further compared risperidone, olanzapine, haloperidol, citalopram and chlordiazepoxide in a standard elevated plus maze
test. Results revealed three distinct anxiolytic-like profiles associated with risperidone, olanzapine and chlordiazepoxide. Risperidone, especially at 1.0 mg/kg, significantly decreased the number of avoidance responses, 22 kHz ultrasonic vocalization, avoidance conditioning-induced hyperthermia and startle reactivity, but did not affect defecations or time spent on the
open arms. Olanzapine (2.0 mg/kg, sc) significantly decreased the number of avoidance responses, 22 kHz vocalization and
amount of defecations, but it did not inhibit startle reactivity and time spent on the open arms. Chlordiazepoxide (10 mg/kg,
ip) significantly decreased the number of 22 kHz vocalization, avoidance conditioning-induced hyperthermia and amount of
defecations, and increased time spent on the open arms, but did not decrease avoidance responses or startle reactivity. Haloperidol and citalopram did not display any anxiolytic-like property in these tests. The results highlight the importance of using multiple measures of fear-related responses to delineate behavioral profiles of psychotherapeutic drugs.
Keywords: Risperidone, Olanzapine, Haloperidol, Chlordiazepoxide, Citalopram, Conditioned avoidance response, Stressinduced hyperthermia, Startle responses, Elevated plus maze, 22 kHz ultrasonic vocalizations

1978; Moore et al., 1994; Moore et al., 1992; Thiessen and Upchurch,
1981; Timmerman et al., 1990). We think that at least two factors
may contribute to this rather confusing literature. First, a wide variety of behavioral models have been used in different studies,
which may not measure the same aspects of fear/anxiety-like responses and may not provide the same assessment of the drug effects. Also, most studies employ only one behavioral task or one
response measure of fear, rather than a series of convergent tasks
to cross-validate the findings. Thus it is difficult to make comparisons across different studies. Second, there are great variations in
the experimental designs (e.g. species, drug doses, timing of drug
administrations, etc.), which may enhance or mask the effect size
of one particular effect and influence data interpretation.
In a recent study (Mead et al., 2008), we evaluated the possible anxiolytic-like property of clozapine and olanzapine, and compared them with the typical antipsychotic haloperidol and chlordiazepoxide (a prototype of sedative–anxiolytic drug). The unique
feature of that study was that we employed two different behavioral models (a fear-induced passive avoidance and conditioned
place aversion paradigm and a two-way active avoidance condi-

1. Introduction
Atypical antipsychotic drugs (APDs) such as risperidone and
olanzapine, have been increasingly used for the treatment of anxiety-related disorders with mixed results (Carson and Kitagawa,
2004). Some case reports suggest that clozapine, olanzapine, quetiapine and risperidone improve symptoms of obsessive–compulsive disorder (OCD) and panic disorder, while an equal number of
reports indicate the worsening effects of each drug on these disorders (Brooke et al., 2005). For other anxiety disorders, such as posttraumatic stress disorder (PTSD), some studies find that atypicals
improve certain symptoms (e.g., hyperarousal and reexperiencing) (Hamner, 1996; Monnelly et al., 2003; Petty et al., 2001), while
others failed to reach the same conclusion (Butterfield et al., 2001;
Hamner et al., 2003).
Preclinical evidence on the intrinsic anxiolytic-like property
of atypical antipsychotics is also inconclusive. Previous studies
have found results that suggest an anxiolytic-like, anxiogenic-like
or no effect on various anxiety-like measures (Ichihara et al., 1988;
Ishida-Tokuda et al., 1996; Karl et al., 2006; Kovacs and de Wied,
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tioning paradigm) and multiple measures of fear/anxiety-like responses (both behavioral as well as physiological) so that our
results were not an artifact of a single model or measure. The conditioned avoidance response model (CAR) is a fear-motivated instrumental conditioning model and is commonly used to study
anti-“psychotic” activity (Bolles, 1970; Levis and Brewer, 2001; Rescorla and Solomon, 1967; Wadenberg and Hicks, 1999). It was
used to study the possible anxiolytic-like effects of antipsychotics
because animals tested in this model show various fear or anxiety-like signs, such as increased body temperature, emission of ultrasonic vocalization (termed 22-KHz USV), and defecation and
urination, which have been routinely used as reliable measures of
conditioned reactive fear as well as to assess anxiolytic-like properties of psychotropic drugs (De Vry et al., 1993; Fanselow, 1986;
Godsil et al., 2000; Sanchez, 2003). Thus we were able to use this
single behavioral paradigm to assess both antipsychotic (as indexed by anti-avoidance effect) and potential anxiolytic-like effects of antipsychotic drugs. Our results show that clozapine and
olanzapine possess an intrinsic anxiolytic-like property, which is
not attributable to their anti-“psychotic” effect or favorable effects
on motor functions or learning and memory processes. Our findings also suggest that the combined use of multiple models is better in differentiating typical and atypical antipsychotics as well as
anxiolytics.
Building on this success, we examined the potential anxiolyticlike property of risperidone and further examined that of olanzapine. We employed a similar multi-measure and multi-task approach (e.g. avoidance conditioning, startle reflex, and elevated
plus maze) and tested drugs at both the acquisition and extinction stages of avoidance conditioning. In Experiment 1, we used a
composite of avoidance conditioning and an acoustic startle reflex
model and examined the dose-dependent effects of risperidone,
citalopram and chlordiazepoxide treatment during the acquisition
phase on the avoidance response as well as on a host of other fear
responses (amount of defecation, ultrasonic vocalization, change
in body temperature, and fear-intensified startle reflex). In Experiments 2 and 3, we used the same model and examined the effects
of risperidone and olanzapine treatment on the extinction of various fear-elicited responses. In Experiment 4, we used a standard
elevated plus maze test (EPM), a more widely used animal model
of anxiety, to cross-validate the findings from the first three experiments. We also compared risperidone and olanzapine with haloperidol, citalopram and chlordiazepoxide in this task.

an arch style doorway (15 cm high × 9 cm wide at base). An aluminum hurdle (4 cm high) was placed between the two compartments, so the rats had to jump from one compartment to the other.
The grid floor consisted of 40 stainless steel rods with a diameter of 0.48 cm, spaced 1.6 cm apart center to center, through which
a scrambled footshock (US, 0.8 mA) was delivered by a constant
current shock generator (Model ENV-410B) and scrambler (Model
ENV-412). The rat location and motor activity was detected by a
set of 16 photobeams (ENV-256-8P) affixed at the bottom of the
box (3.5 cm above the grid floor). Two houselights (28 V) were
mounted at the top of each compartment. The CS was a 76 dB
white noise produced by a speaker (ENV 224AMX) mounted on
the ceiling of the cubicle, centered above the shuttle box. All the
training and testing procedures were controlled by Med Associates programs running on a computer. Background noise (approximately 74 dB) was provided by a ventilation fan affixed at the top
corner of each isolation cubicle.
In each CAR box, an ultrasonic vocalization microphone (P48
Avisoft Bioacoustics/Emkay Microphone, Avisoft Bioacoustics,
Berlin, Germany) was mounted on the ceiling of the two-compartment chamber. The microphone was connected via an E-MU 0404
USB Audio device to a computer. Acoustic data were displayed
in real time by the Avisoft RECORDER, a multi-channel triggering hard-disk recording software (version 3.4; Avisoft Bioacoustics), and were recorded at a sampling rate of 192 kHz in 16 bit
format and analyzed by Avisoft SASLab Pro (version 4.51; Avisoft
Bioacoustics).

2. Materials and methods

The elevated plus maze (EPM) was situated in a room with
an illuminance of about 52 lx. It consisted of two open arms
(50 cm×10 cm), two enclosed arms (50 cm×10 cm) and a central
platform (10 cm×10 cm) made of black polycarbonate plastic. Each
arm was supported by a sturdy plastic leg and was elevated 50 cm
above the floor. The two enclosed arms had high walls (38.5 cm
in height), while the two open arms had raised edges (1.0 cm in
height) along each side and end to decrease the possibility of falling during drug testing (Fernandes and File, 1996). Behavior was
digitally recorded on a computer located in an adjacent room and
automatically scored via Biobserve Viewer video tracking software (Biobserve, Germany).

2.1. Subjects
Male Sprague–Dawley rats (250–275 g upon arrival, Charles River,
Portage, MI) were housed two per cage, in 48.3 cm × 26.7 cm × 20.
3 cm transparent polycarbonate cages under 12-h light/dark conditions (light on between 6:00 am and 6:00 pm). Room temperature was maintained at 22 ± 1 with a relative humidity of 55–60%.
Food and water was available ad libitum. Animals were allowed at
least one week of habituation to the animal facility before being
used in experiments. All procedures were approved by the animal
care committees at the University of Nebraska-Lincoln.
2.2. Conditioned avoidance response and ultrasonic vocalization
recording apparatus
Four identical two-way shuttle boxes custom designed and manufactured by Med Associates (St. Albans, VT) were used. Each
box was housed in a ventilated, sound-insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm
long, 30 cm high (from grid floor) and 24 cm wide, and divided
into two equal-sized compartments by a white PVC partition with

2.3. Acoustic startle reflex apparatus
Four startle monitor systems (Kinder Scientific, Julian, CA),
controlled by a PC were used as the testing apparatus. They
were housed in compact sound attenuation cabinets (35.56 cm
wide × 27.62 cm deep × 49.53 cm high). A speaker (diameter: 11 cm) mounted on the cabinet’s ceiling was used to generate acoustic stimuli (70 dB–120 dB white noise). The startle activity was measured by a piezoelectric sensing platform on the floor.
During testing, rats were placed in a rectangular box made of
transparent Plexiglas (19 cm wide × 9.8 cm deep × 14.6 high) with
an adjustable ceiling, providing only limited restraint while prohibiting ambulation.
2.4. Elevated plus maze apparatus

2.5. Drugs
The injection solutions of haloperidol (HAL, 5.0 mg/ml ampoules,
Sicor Pharmaceuticals, Inc, Irvine, CA) and chlordiazepoxide (CDP,
Sigma-Aldrich, St. Louis, MO) were obtained by mixing drugs with
sterile water. Olanzapine (OLZ, Toronto Research Chemicals Inc,
Ontario, Canada) and risperidone (RIS, a gift from the NIMH drug
supply program) were dissolved in 1.0–1.5% glacial acetic acid in
sterile water. Citalopram (CIT, Toronto Research Chemicals Inc.,
Ontario, Canada) was dissolved in 0.9% physiological saline.
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2.6. Experiment 1: Effects of risperidone, chlordiazepoxide and
citalopram treatment during the acquisition phase of a composite
CAR and startle reflex task on various fear/anxiety-like responses
Forty-eight rats were first habituated to the CAR boxes and startle boxes for 3 consecutive days (20 min in each box/day). On
each habituation day, 1 h after injection of sterile water, rats were
placed in the CAR boxes. The number of 22 kHz USV and amount
of defecation (in mg) in the CAR boxes were recorded. Body temperature was measured using a probe (lubricated with mineral oil)
inserted in the rectum (Thermalert TH-5, Physitemp, Clifton, NJ,
USA) immediately before and after the CAR box exposure (20 min
interval). Then, they were placed in the startle reflex boxes and exposed to the background noise (70 dB) for 20 min before being returned to their home cages.
After the habituation, they were randomly assigned to 6 groups
(n = 8/group): vehicle (sterile water), RIS 0.2 mg/kg, 0.33 mg/kg,
1.0 mg/kg, CDP 10.0 mg/kg or CIT 10.0 mg/kg, and trained/tested
under drug for 7 consecutive days, followed by 3 drug-free tests.
We tested three doses of RIS, which covered subclinical, clinical and
superclinical doses in terms of D2 receptor occupancy (50%–80%) to
explore its dose-dependent effect (Kapur et al., 2003). CDP and CIT,
two non-antipsychotic drugs were included as comparisons (Griebel
et al., 1994; Mead et al., in press; Sanchez, 2003). Each daily drug test
consisted of two components: a 20-trial two-way CAR session and
a startle session. Rats were first injected with RIS, CDP, CIT or vehicle, and their body temperature was measured 0.5 h (in the case
of CDP) or 1 h later (in the case of other treatments) (Mead and Li,
in press). Then, they were placed in the CAR boxes and trained for
20 trials. Each trial started by presenting a white noise (CS) for 10 s,
followed by a continuous scrambled footshock (0.8 mA, US, maximum 5 s) on the grid floor. If a subject moved from one compartment into the other within the 10 s of CS presentation, it avoided
the shock, and this shuttling response was recorded as avoidance.
If the rat remained in the same compartment for more than 10 s and
made a crossing upon receiving the footshock, this response was recorded as escape. If the animal did not respond during the entire 5 s
presentation of the shock, the trial was terminated and escape failure was recorded. Intertrial intervals varied randomly between 30 s
and 60 s (mean = 45 s). The number of avoidance responses (max:
20) was calculated as the main dependent variable for avoidance responding. Fecal matter was collected at the end of CAR session and
weighed on a Mettler Toledo scale (< 0.1 mg). Ultrasonic vocalizations at the 22 kHz range (20–32 kHz) were recorded using Avisoft
Recorder software (Version 3.4). Settings included sampling rate
at 192 kHz, format 16 bit. For acoustical analysis, recordings were
transferred to Avisoft SASLab Pro (Version 4.51) and a fast Fourier transformation (FFT) was conducted. Spectrograms were generated with an FFT-length of 256 points and a time window overlap of 50% (100% Frame, FlatTop window). The spectrogram was
produced at a frequency resolution of 750 Hz and a time resolution of 0.6667 ms. Call detection was provided by an automatic single threshold-based algorithm (threshold: −20 dB) and a hold-time
mechanism (hold-time: 0.02 s).
Immediately after the rats completed the CAR component of
testing, they were placed in the acoustic startle boxes and tested
for startle responses under 6 trial conditions (Davis, 1986; Walker
and Davis, 2002). During the 5 min acclimation period (background
noise set at 70 dB), activity was sampled for 100 ms every 60 s. After the acclimation period, 15 startle-eliciting stimuli (leaders) were
given in a pseudorandom order, five at each of three different intensities (95, 100, and 105 dB, 50 ms in duration). The leaders were
used to familiarize the rats to the acoustic stimuli and were not
used for statistical analysis. Following the leaders, another 30 startle
stimuli were presented, five for each type at three dB levels (95 dB,
100 dB, 105 dB alone; 76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB)
with a 30 s intertrial interval. For the 95 dB, 100 dB and 105 dB
alone trials, startle activity was sampled for 50 ms immediately af-
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ter the white startle noise (95, 100, or 105 dB) was presented. For the
76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB trials, a 76 dB white
noise was presented first for 3.2 s, followed 10 ms later by one of
the white startle noises (95, 100, or 105 dB) for 50 ms. Again, startle
activity was sampled for 50 ms immediately after the white startle
noise (95, 100, 105 dB) was presented. This 76 dB white noise was
identical to the CS used in the CAR. It was hypothesized that startle
activity under this condition encompasses an acquired fear component (“conditioned fear”), whereas startle activity under the startle
noise-alone condition reflects an innate fear (“unconditioned fear”).
Whole body startle responses were recorded in Newtons.
One day after the last training session, all rats were continuously tested drug-free for an additional 3 sessions under the CSalone (no shock) condition. The procedure described above was
employed identically except that the footshock was omitted.
2.7. Experiment 2: Effects of risperidone treatment (1.0 mg/kg) on
the extinction of various fear/anxiety-like responses in the CARtrained rats
Experiment 1 showed that RIS at 1.0 mg/kg exhibited a robust
and consistent anxiolytic-like effect in the rats that were trained
in the CAR. This experiment examined whether RIS at 1.0 mg/kg
also exhibits a robust anxiolytic-like effect in rats that had already
acquired avoidance behavior.
Thirty-six rats were first habituated to the CAR boxes for 2 days
(20 min/day). Then, they were trained in the CAR for 10 sessions.
The first 9 sessions used 20 trials, while the last session used 30 trials, in which the number of 22 kHz USV and amount of defecation were also recorded. Rats were then semi-randomly assigned to
one of four groups matched for avoidance performance on the last
training day (baseline): VEH-I (water, sc, n = 9), VEH-D (water, sc,
n = 9), RIS-I (1.0 mg/kg, sc, n = 9) and RIS-D (1.0 mg/kg, sc, n = 9)
and tested daily 1 h after RIS or vehicle treatment under the CS-only
(no shock, 30 trials/daily session) condition for 3 consecutive days.
In each test, the CS was immediately terminated after a rat made an
avoidance response for rats in the VEH-I and RIS-I conditions (“I”
stands for “Immediate”), or the CS remained on for another 5 seconds after a rat made an avoidance response for rats in the VEH-D
and RIS-D conditions (“D” stands for “Delayed”). This delayed CS
condition is known to cause increased fear and facilitate avoidance
decline in the CAR-trained rats (Bolles and Grossen, 1970; Kamin,
1956). Each daily test began 60 min after RIS or vehicle administration, and each test session consisted of 30 trials. Immediately after
being taken out from the CAR boxes, rats were placed in one of four
startle boxes for startle activity testing. One day after the 3 days of
drug testing, rats were tested drug-free in two additional CS-only
sessions (30 trials/session) to examine the post-treatment effect.
2.8. Experiment 3: Effects of olanzapine treatment (2.0 mg/kg) on
the extinction of various fear/anxiety-like responses in the CARtrained rats
This experiment was identical to that of Experiment 2 with a couple of exceptions. First, 40 rats instead of 36 were used. Second,
OLZ at 2.0 mg/kg was tested. Our previous work shows that
when administrated during the acquisition phase of CAR, OLZ at
2.0 mg/kg significantly inhibited the body temperature increase
and fear-induced defecation (Mead and Li, in press). This work
further investigated the anxiolytic-like effect of OLZ on the extinction of various fear-elicited responses.
2.9. Experiment 4: Effects of risperidone, olanzapine, haloperidol,
chlordiazepoxide and citalopram treatment on an elevated plus
maze test
Rats were first handled for two days (2 min/day/rat). On the testing day, they were first injected with RIS (0.33 or 1.0 mg/kg, sc,
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n = 8/group), OLZ (0.5 or 1.0 mg/kg, sc, n = 9 and 8 respectively),
HAL (0.03 or 0.05 mg/kg, sc, n = 8 and 9 respectively), CIT (10 mg/
kg, sc, n = 10), CDP (10 mg/kg, ip, n = 18) or vehicle (sterile water,
n = 18). One hour later (or 0.5 h later for CDP rats), rats were individually placed in the central part of the maze facing one of the enclosed arms. The numbers of entries made into enclosed and open
arms and time spent in enclosed and open arms were automatically
recorded for 5 min using a video tracking system (Biobserve, Germany). An arm entry was defined as all four paws being placed on
an arm. The subjects were run in batches, with a requirement that
each batch contained at least 2 vehicle and two CDP controls. RIS
and OLZ were assessed first, followed by tests on HAL and CIT.
2.10. Statistical analysis
Data were expressed as mean values ± SEM and were analyzed using a factorial repeated measures analysis of variance (ANOVA)
with the between-subjects factor being treatment and/or group
condition (e.g. RIS vs. VEH, immediate CS vs. delayed CS, etc.) and
the within-subject factor being the test sessions (e.g. day 1 test, day
2 test, etc.) or test conditions (e.g. startle levels). Post hoc LSD tests
were used to identify any possible drug treatment effect in comparison to vehicle control. To examine group difference on specific test
days, one-way ANOVAs and post hoc tests were used. A conventional two-tailed level of significance at the 5% level was required.
3. Results
3.1. Experiment 1: Effects of risperidone, chlordiazepoxide and
citalopram treatment during the acquisition phase of a composite
CAR and startle reflex task on various fear/anxiety-like responses
3.1.1. Avoidance response — Repeated measures ANOVA revealed a main effect of “treatment” (F(5,42) = 8.671, p < 0.001),
“session” (F(6,252) = 47.202, p < 0.001) and a significant
“treatment” × “session” interaction (F(30,252) = 3.555, p < 0.001).
Post hoc tests indicated that only the RIS 1.0 mg/kg group differed
significantly from the vehicle group (p < 0.001). Rats treated with
CDP (10 mg/kg), CIT (10 mg/kg), RIS (0.2 and 0.33 mg/kg) or vehicle (distilled water) all showed a steady improvement in avoidance responding. On the three subsequent drug-free CS-only test
days, once again, only the RIS 1.0 group still showed significantly
fewer avoidance responses than the other drug groups (p < 0.001).
These data were originally reported as Figure 4 in Mead and Li (in
press) for the purpose of studying the behavioral mechanisms of
antipsychotic action in the CAR. None of the following data was
reported before.

Figure 1. Mean (+ SEM) numbers of 22 kHz ultrasonic vocalization (A) that the rats made throughout the habituation, seven CAR training days and three drug-free test
days. *p < 0.05 significantly different from the vehicle
group.
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3.1.2. 22 kHz USV — During the 7 CAR training days, the number
of USV showed a progressive decline (F(6,252) = 21.179, p < 0.001;
Figure 1). RIS (1.0 mg/kg) and CDP (10 mg/kg) decreased the
number of 22 kHz USV in comparison to the vehicle treatment (a
significant “treatment” × “session” interaction, F(30,252) = 2.299,
p < 0.001). One-way ANOVAs on each CAR training day showed
that RIS (1.0 mg/kg) was significantly different from the vehicle on day 1 (p = 0.020), day 2 (p = 0.010), day 3 (p = 0.014), day
4 (p = 0.040), and day 7 (p = 0.035). CDP (10 mg/kg) was significantly different from the vehicle on day 4 (p = 0.027), day 5
(p = 0.048), and day 7 (p = 0.040). On the 3 drug-free CS-only test
days, all groups exhibited fewer USV and no group difference
was detected (“treatment”: F(5,42) = 1.531, p = 0.201; “session”:
F(2,84) = 2.445, p = 0.093; “treatment” × “session” interaction,
F(10,84) = 0.714, p = 0.709).
3.1.3. Defecations and body temperature change — During the habituation days, both measures remained low, and no significant group
difference was detected (all ps > 0.05). During the CAR training
phase, RIS (0.2, 1.0 mg/kg) and CDP (10 mg/kg) significantly decreased the avoidance conditioning-induced increase in body temperature (RIS 0.2 vs. VEH, p = 0.050; RIS 1.0 vs. VEH, p = 0.005;
CDP vs. VEH, p = 0.017, data not shown). CDP, but not RIS or CIT,
also significantly decreased the amount of defecation (p = 0.019).
During the drug-free test phase, the effects of RIS and CDP were
no longer present (all ps > 0.05, data not shown). Interestingly, the
RIS (1.0 mg/kg) rats defecated significantly more than the vehicle
rats (p = 0.020), indicating a drug-withdrawal-induced rebound.
3.1.4. Startle responses — To simplify data presentation, we first
averaged each rat’s startle activity data under the three startlealone conditions (95 dB, 100 dB, 105 dB alone) and three CS + startle conditions (76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB)
separately. We then calculated the percent changes in the average startle activity for each rat from the pre-CAR day (i.e. the
3rd and last habituation day) to each of 7 drug test days and 3
drug-free test days. Finally, we averaged the percent changes for
the 7 drug days and 3 drug-free days separately. Results are presented in Figure 2. During the drug test phase, RIS, but not CDP
or CIT, suppressed the percent change of the mean startle activity
from the baseline, and this suppressive effect of RIS disappeared
when the drug treatment stopped. On the drug testing data, repeated measures ANOVA (drug treatment as a between-subjects
factor and startle testing conditions (i.e. startle-alone or CS + startle) as a within-subjects factor) revealed a main effect of “testing
condition” (F(1,42) = 5.491, p = 0.024), “treatment” (F(5,42) = 4.764,
p = 0.002), but no significant “testing condition” × “treatment” in-
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teraction (F(5,42)=1.348, p = 0.263). One-way ANOVAs on group
differences indicated that the three RIS groups differed significantly from the vehicle group only under the CS + startle conditions (p = 0.012, 0.023 and 0.005 for RIS 0.2, 0.33 and 1.0 mg/
kg respectively), but not under the startle-alone conditions (all
ps > 0.05). To the extent that startle activity under the CS + startle
conditions reflects an acquired fear (“conditioned fear”), whereas
startle activity under the startle-alone condition reflects an innate
fear (“unconditioned fear”), this result suggests that RIS may preferentially inhibit conditioned fear over unconditioned fear. During the drug-free test phase, the RIS treatment effect was no longer present (p > 0.05).
3.2. Experiment 2: Effects of risperidone treatment (1.0 mg/kg) on
the extinction of various fear/anxiety-like responses in the CARtrained rats
3.2.1. Avoidance response — Figure 3A shows the number of conditioned avoidance responses in the four groups over the three phases
(baseline, three drug test days and two drug-free days). RIS (1.0 mg/
kg) significantly suppressed avoidance responding (F(1,32) = 85.787,
p < 0.001), and the delayed termination of CS also caused a progressive decline in avoidance responding (F(1,32) = 4.645, p = 0.0390)
during the drug test days. There was also a significant 3-way interaction among “treatment”, “condition” and “test day” (days 1,
2 and 3) (F(2,64) = 6.328, p = 0.003). No group difference during the
two drug-free test days was detected (ps > 0.05).
3.2.2. 22 kHz USV and defecations — During the drug test phase, RIS
significantly decreased the number of 22 kHz vocalization calls in
the well-trained rats (a main effect of “treatment: F(1,32) = 6.335,
p = 0.017, Figure 3B), but did not decrease the amount of defecation (F(1,32) = 2.329, p = 0.137, Figure 3C). These findings were
consistent with what we observed in Experiment 1. The CS testing condition did not impact both measures of fear (22 kHz
USVs: F(1,32) = 0.191, p = 0.665; defecations: F(1,32) = 0.107,
p = 0.746), nor did it interact with the RIS treatment on these
measures (22 kHz USVs: F(1,32) = 0.332, p = 0.569; defecations:
F(1,32) = 1.695, p = 0.202). No treatment effect or testing condition
effect was present on the drug-free test days (ps > 0.05).
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days). OLZ (2.0 mg/kg) significantly suppressed avoidance responding (F(1,36) = 40.618, p < 0.001), and the delayed termination of CS also caused a decrease in avoidance responding
(F(1,36) = 5.05, p = 0.031). There was also a main effect of “test day”
(F(2,72) = 7.439, p = 0.001), and a significant “treatment” × “test
day” interaction (F(2,72) = 3.392, p = 0.039). There was no group
difference during the two drug-free test days (ps > 0.4).
3.3.2. 22 kHz USV and defecations — During the drug test phase,
OLZ significantly decreased the number of 22 kHz calls (a main
effect of “treatment: F(1,36) = 5.715, p = 0.022, Figure 4B) and the
amount of defecation (F(1,36)=12.513, p = 0.001, Figure 4C) in the
well-trained rats. The CS testing condition did not impact both
measures of fear (22 kHz USVs: F(1,36) = 0.439, p = 0.512; defecations: F(1,36) = 0.738, p = 0.396), nor did it interact with the
OLZ treatment on these measures (22 kHz USVs: F(1,36) = 0.637,
p = 0.430; defecations: F(1,36) = 1.504, p = 0.228). No treatment effect or testing condition effect was present during the drug-free
test phase (all ps > 0.05).
3.3.3. Startle responses — During the drug test phase, OLZ at 2.0 mg/
kg did not significantly decrease the mean percent startle activity
change (Figure 4D). There was no significant main effect of “treatment” (F(1,36) = 1.723, p = 0.198), no main effect of CAR testing
condition (immediate vs. delayed CS, F(1,36) = 2.105, p = 0.155) or
their interaction (F(1,36) = 0.374, p = 0.545). However, the mean percent startle activity change was significantly affected by the startle
testing conditions (i.e. the CS + startle or startle-alone condition)
(F(1,36) = 25.847, p < 0.001), with rats showing less decrease under
the startle-alone condition than under the CS + startle condition.
During the drug-free test phase, no significant treatment or CAR
testing condition was found (Figure 4E, all ps > 0.05).

3.2.3. Startle responses — RIS significantly decreased the mean percent startle activity change from the pre-drug day (the last CAR
training day) to the drug test days (Figure 3D). There was a significant main effect of “treatment” (F(1,32) = 9.581, p = 0.004), but
no main effect of CAR testing condition (immediate vs. delayed
CS, p = 0.59). No significant interaction effect was found (p > 0.59).
The mean percent startle activity change was also not affected by
the startle testing conditions (i.e. the CS + startle or startle-alone
condition) (F(1,32) = 0.618, p = 0.438). One-way ANOVAs on the
group differences indicated that the two RIS groups differed significantly from the two vehicle groups, mainly under the CS + startle conditions (ps = 0.019–0.049), again suggesting that RIS preferentially inhibits startle activity that encompasses a conditioned
fear component. The RIS-I group also showed a significant difference from the VEH-I group under the startle-alone condition
(p = 0.019). The RIS effect disappeared when the drug treatment
stopped as no significant effect with “treatment”, “testing condition” or their interactions was found (Figure 3E, all ps > 0.05).
3.3. Experiment 3: Effects of olanzapine treatment (2.0 mg/kg) on
the extinction of various fear/anxiety-like responses in the CARtrained rats
3.3.1. Avoidance response — Figure 4A shows the number of conditioned avoidance responses in the four groups over the
three phases (baseline, three drug test days and two drug-free

Figure 2. Mean (+ SEM) percent change from the baseline (the predrug day) to the drug test days of the averaged startle activity under the CS + startle conditions (i.e., 76 dB + 95 dB, 76 dB + 100 dB,
76 dB + 105 dB) and the startle-alone conditions (i.e., 95 dB, 100 dB,
105 dB alone) (A) and drug-free test days (B). *p < 0.05 significantly
different from the vehicle group.
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3.4. Experiment 4: Effects of risperidone, olanzapine, haloperidol,
chlordiazepoxide and citalopram treatment on an elevated plus
maze test
During the test, 1 rat in the CDP group and 1 rat in the OLZ
1.0 mg/kg fell off from the maze, and their data were not included in the analysis (Walf and Frye, 2007). A repeated measures ANOVA on the time spent on the open arms (a withinsubjects factor) revealed a significant effect of “treatment”
(F(8,85) = 2.137, p = 0.041), “arm” (F(1,85) = 111.248, p < 0.001)
and “treatment” × “arm” interaction (F(8,85) = 3.252, p = 0.003).
Similar analysis on the entries to the open arms also revealed
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a significant effect of “treatment” (F(8,85) = 2.573, p = 0.015),
“arm” (F(1,85) = 53.718, p < 0.001) and “treatment” × “arm”
interaction (F(8,85) = 3.154, p = 0.004), suggesting that different drug treatments differentially affected time spent on the
open and closed arms and the number of entries to the open
and closed arms. One-way ANOVAs showed that only CDP
(10.0 mg/kg) significantly increased time spent on the open
arms (Figure 5A, ps = 0.011 vs. VEH). In addition, OLZ (1.0 mg/
kg), RIS (1.0 mg/kg) and HAL (0.05 mg/kg) significantly decreased the number of entries to the open arms (Figure 5B,
ps = 0.013, 0.02 and 0.049 respectively), suggesting a possible
motor impairment effect.

Figure 3. Mean (+ SEM) numbers of avoidance responses (A), 22 kHz USV counts (B), amount of defecations (C), percent change of the averaged
startle activity under the CS + startle and the startle-alone conditions from the baseline to the drug days (D), and to the drug-free days (E) of the
four groups of rats that were treated with risperidone (1.0 mg/kg, sc) or vehicle (sterile water) and tested under the immediate CS termination
(RIS-I and VEH-I) or the delayed CS termination condition (RIS-D and VEH-D). *p < 0.05 significantly different from the vehicle group.
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4. Discussions
Table 1 summarizes the effects of risperidone, olanzapine and chlordiazepoxide treatment on various fear and anxiety-like responses
found in the present study. Three distinct anxiolytic-like profiles
are apparent. Risperidone (1.0 mg/kg, sc) was efficacious against
an increase in 22 kHz USV, body temperature, and startle reactivity
elicited by conditioned fear, but was ineffective in decreasing the
amount of defecations and increasing time spent on the open arms.
Olanzapine (2.0 mg/kg, sc) was efficacious against an increase in
22 kHz USV and amount of defecations induced by fear, but was in-
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effective in decreasing startle reactivity and time spent on the open
arms. Chlordiazepoxide (10 mg/kg, ip) was efficacious against an
increase in 22 kHz USV, body temperature, and amount of defecations. It also increased time spent on the open arms, but was ineffective in decreasing startle reactivity. This study, together with our
previous report (Mead and Li, in press), and others (Moore et al.,
1994; Moore et al., 1992; Wiley et al., 1993), strongly suggests that risperidone and olanzapine possess an anxiolytic-like property. Our
results also indicate that haloperidol and citalopram, at least upon
acute administration, did not seem to possess any anxiolytic-like
properties, as seen in these fear/anxiety-like measures.

Figure 4. Mean (+ SEM) numbers of avoidance responses (A), 22 kHz USV counts (B), amount of defecations (C), percent change of the averaged
startle activity under the CS + startle and the startle-alone conditions from the baseline to the drug days (D), and to the drug-free days (E) of the
four groups of rats that were treated with olanzapine (2.0 mg/kg, sc) or vehicle (sterile water) and tested under the immediate CS termination
(OLZ-I and VEH-I) or the delayed CS termination condition (OLZ-D and VEH-D). *p < 0.05 significantly different from the vehicle group.
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Figure 5. Mean (+ SEM) time in seconds spent on the open and closed
arms (A) and mean numbers of entries to the open and closed arms
(B) of the rats that were treated with various doses of risperidone (0.33
or 1.0 mg/kg), olanzapine (0.5 or 1.0 mg/kg), haloperidol (0.03 or
0.05 mg/kg), chlordiazepoxide (10 mg/kg), citalopram (10 mg/kg), or
vehicle (sterile water). *p < 0.05 significantly different from the vehicle group.

Our results highlight the importance of using multiple measures of fear/anxiety-like responses from several animal models
to delineate behavioral profiles of psychotherapeutic drugs. As
our results show, no two drugs are the same. A drug may be efficacious in lowering levels of fear shown in some measures but not
in others. Therefore, it is insufficient to rely on a single measure of
fear or anxiety-like behavior to determine an anxiolytic-like profile of a drug. With multiple measures of fear/anxiety-like behavior, we not only determined that risperidone and olanzapine have
an anxiolytic-like property, but also shed light against which aspects of fear or anxiety-like responses that risperidone, olanzapine or chlordiazepoxide is most effective. This work may be potentially useful in helping better understand the neural basis of
the specific drug effects given the fact that each measurement of
fear or anxiety-like responses (body temperature, ultrasonic vocalizations, defecation and urination) may be subserved by a distinct
pathway from the central amygdala to a variety of brainstem regions (Davis and Whalen, 2001).
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The present study extended our previous work (Mead and Li, in
press) in the following three directions. First, we examined risperidone, another widely prescribed second generation antipsychotic
drug with a billion dollar revenue comparable to that of olanzapine. Second, we examined risperidone at both the acquisition and
extinction phases of avoidance conditioning, and olanzapine at the
extinction phase. Mead et al. (2008) only examined olanzapine at the
acquisition phase. In Mead et al. (2008), we did not observe any decreasing effect of olanzapine on 22 kHz USV, whereas in the present
study we did. This discrepancy may be due to the methodological
differences. In Mead et al. (2008), olanzapine was given to rats that
still experienced footshock at the acquisition phase, whereas in the
present study, olanzapine was given to rats that were tested with
only the CS at the extinction phase. Thus, the 22 kHz USV in Mead
et al. (2008) still consisted of those that were elicited by footshock
(an unconditioned fear), on which olanzapine may be less effective. Siemiatkowski et al. (2001) also reported that acute treatment
with olanzapine (1.0 mg/kg, ip) reduced the pre-shock contextual
22 kHz USV (a measurement of a “conditioned fear”) but not the
shock-elicited ultrasonic vocalizations. These findings suggest that
olanzapine may be less effective against measurements of unconditioned fear than those of conditioned fear, a notion supported by its
lack of effects on the EPM and startle reflex task (see below), and on
the open field and holeboard test (Frye and Seliga, 2003).
Third, we incorporated an acoustic startle reflex test component in the two-way conditioned avoidance task. In each acoustic startle test, the rats were tested under both CS + startle and
startle-alone conditions, reflecting putative “conditioned fear”
and “unconditioned fear” respectively. Our results indicate that
risperidone preferentially inhibits the conditioned fear-elicited
startle reactivity over the innate fear-elicited one, whereas olanzapine does not inhibit either component. These profiles of risperidone and olanzapine are consistent with clinical (Wynn et al.,
2007) and preclinical work (Le Pen and Moreau, 2002; Moore et al.,
1994; Swerdlow et al., 1996; Wiley et al., 1993) showing that risperidone and olanzapine generally do not decrease startle reactivity
under the startle-alone conditions. These results are also consistent with the findings from the EPM test (Experiment 4) in which
both risperidone and olanzapine did not affect the time spent and
number of entries to the open arms, two measures of “unconditioned” fear/anxiety-like behavior (Walf and Frye, 2007). We are
not aware of any previous work that has investigated the risperidone effect on the EPM. Our finding of olanzapine on the EPM is
consistent with a recent study showing that olanzapine (0.5 mg/
kg, ip) has little effect on anxiety-like behavior in the EPM test in
normal rats, but shows an attenuation effect only in rats that have
received an inescapable stress prior to the test on EPM (Locchi et
al., 2008). However, this finding was inconsistent with that of Frye
and Seliga (2003) who reported that olanzapine (5.0 or 10.0 mg/
kg, ip) significantly increased time on the open arms. This difference may simply be due to dose differences. It is possible that only
at a much higher dose does olanzapine exhibit an anxiolytic-like
effect in the EPM. Because olanzapine at 1.0 mg/kg was effective
on several measures of conditioned fear (e.g., CS-elicited 22 kHz
USV, body temperature change, and defections), the EPM studies
may indicate that in order to inhibit unconditioned fear (as mea-

Table 1. Summary of the effects of risperidone, olanzapine and chlordiazepoxide treatment on various fear and anxiety-like responses.
22 kHz USV
Risperidone
Olanzapine
Chlordiazepoxide

↓
↓
↓

Defecation
_
↓
↓

Body temperature
increase
↓
↓*
↓

Startle reflex
↓
–
–

“ ↑ ”: denotes a significant increasing effect. “ ↓ ” : denotes a significant decreasing effect.
“ _ ” denotes no effect. “ * ”: the finding obtained from Mead et al. (2008).

Open arm time
in EPM
–
–
↑

Active avoidance
responding
↓
↓
–

306

sun, he, hu,

sured in the EPM), a much higher dose of olanzapine may be required. More studies are needed to further determine whether risperidone and olanzapine at clinical relevant doses (Kapur et al.,
2003) are truly more efficacious against conditioned fear versus
unconditioned fear.
The neurobiological mechanism(s) of the anxiolytic-like action of olanzapine has implicated allopregnanolone, a metabolite
of progesterone as an important molecule (Frye and Seliga, 2003;
Ugale et al., 2004). Marx et al. (2006b; 2003) found that olanzapine can dose-dependently increase allopregnanolone in the rat
cerebral cortex and hippocampus (Marx et al., 2006a; Marx et al.,
2006b; Marx et al., 2003). Frye and Seliga (2003) also found that
olanzapine’s anxiolytic-like effect coincides with its enhancing action on brain allopregnanolone (Frye and Seliga, 2003). Since allopregnanolone acts as a positive modulator of the GABAA receptor
(Majewska, 1990) and shows a strong anxiolytic-like effect in the
EPM task and the Geller–Seifter conflict test (Akwa et al., 1999; Bitran et al., 2000; Brot et al., 1997), it is therefore possible that olanzapine-induced elevations in allopregnanolone may contribute to
their anxiolytic-like effect. On the other hand, the neurobiological
mechanisms that mediate the anxiolytic-like action of risperidone
are less clear. Because risperidone has a complex multiple-receptor binding profile, with higher affinities for D2, D3, and 5-HT2A,
5-HT7 receptors but weaker affinities to D4, 5-HT6, histaminic H1,
and muscarinic m1 receptors (Horacek et al., 2006; Miyamoto et al.,
2005; Seeman, 2006), it is difficult to pinpoint which receptor action or actions account for its anxiolytic-like action. Since risperidone’s antagonist action on 5-HT2A receptors has been suggested
to be important for the improved therapeutic effects of risperidone on negative symptoms of schizophrenia, it is possible that
risperidone may exhibit an anti-anxiety-like effect by antagonizing 5-HT2A receptors, especially the ones located on glutamatergic
pyramidal neurons and GABAergic interneurons in the cortex and
hippocampus (Meltzer et al., 2003). Future research should direct
attention to test this hypothesis.
In summary, the present study demonstrates that atypical
APDs such as risperidone and olanzapine do possess an anxiolytic-like efficacy in addition to their antipsychotic efficacy. This
additional efficacy is different from that of chlordiazepoxide, a traditional anxiolytic drug. Our findings are important because they
can be utilized to develop methods of ameliorating anxiety or fear
in schizophrenics (Blin et al., 1996) and provide some guidelines
on which drug to use for different manifestations (e.g., behavioral,
emotional, and physiological, etc.) of anxiety symptoms.
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